viewDeepVerge PLC

Integumen PLC - Exercise of Warrant Shares and Call Option Shares

RNS Number : 5987B
Integumen PLC
10 June 2019

AIM share code: SKIN


10 June 2019


Integumen PLC


("Integumen" or "Company")



Exercise of Warrant Shares and Call Option Shares


Integumen announces that it has received notification of the exercise of call options over 1,111,111 shares in the issued share capital of Integumen ("the Call Option Shares"). The exercise of the Call Option Shares amounts, in aggregate, to a cash value of £177.  The Company also announces that it has received notification of the exercise of warrants over 5,000,000 shares in the issued share capital of Integumen ("the Warrant Shares"). The exercise of the Warrant Shares amounts, in aggregate, to a cash value of £75,000.


The Call Option Shares and the Warrant Shares are expected to be admitted to trading on AIM on or about 14 June 2019 and will rank pari passu with the ordinary shares of the Company in issue.


Total voting rights


The Company's total issued capital, after the issue of the Call Option Shares, will be 960,284,795 ordinary shares. As the Company does not hold any shares in Treasury, this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company following Admission.




Integumen plc

Gerard Brandon, CEO


+44 (0) 7340 055 643

SPARK Advisory Partners Limited

(Nominated Adviser)


Neil Baldwin/Andrew Emmott

+44 (0) 113 370 8974

Turner Pope Investments (TPI) Limited (Broker)

Andy Thacker

+44 (0) 20 3621 4120


About Integumen:


Integumen is a vertically integrated business, collaborating their Labskin technology platform with partners in artificial intelligence, clinical research, medical device and life science. These collaborators are building their own technology on top of the Labskin AI backbone. Labskin allows skin-care, health-care, pharmaceutical manufacturers and cosmetic companies to test their products on human-like skin in a real-world environment with full access to multiple state-of-the-art partner technologies.


The Company combines data analytics with access to therapeutic operational expertise and offers solutions to our clients, from regulatory approvals, right through to marketing fully tested ingredients that have been certified on our Laboratory grown living human tissue.



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Quick facts: DeepVerge PLC

Price: -

Market: AIM
Market Cap: -

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Market report: FTSE lacks direction and Japan's PM resigns

An up and down start for the FTSE 100 today following the news Japan's longest-serving Prime Minister has resigned due to health issues. Other main headlines today - Walmart (NYSE:WMT) has confirmed it's joining forces with Microsoft in a bid for the US assets of TikTok. It comes just...

on 08/28/2020

3 min read